2015 Antineoplastics

Bone marrow suppression is the dose-limiting complication of many antineoplastic drugs.  Recombinant forms of several lineage-dependent colony stimulating factors have been developed.  These factors activate specific progenitor cells, resulting in the production of:  ERYTHROPOIETIN à red blood cells, FILGRASTIM (G-CSF) à neutrophils, SAGRAMOSTIM (GM-CSF) à granulocytes, eosinophils, basophils and monocytes and INTERLEUKIN 11 and ROMIPLOSTIM à platelets.